Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04838600
Other study ID # PN-00025
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date June 7, 2021
Est. completion date November 20, 2023

Study information

Verified date August 2023
Source RLS Global
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a single-arm, observational, multicenter PMCF investigation designed to confirm clinical performance and safety of ChloraSolv when exposed to larger population of clinical users. Approximately 65 subjects will be enrolled (calculated dropout range 20%) from at least 6-12 sites in Sweden. Subjects presented with chronic leg ulcers and chronic diabetic foot ulcers in need of debridement will be enrolled and receive application of ChloraSolv per clinical routine at treating site and in accordance with the ChloraSolv Instruction for Use for up to 24 weeks. Subjects will attend a baseline visit to assess eligibility and collect demographic and baseline data and initiate treatment. There will be two follow up visits in the investigation. The first follow up visit will take place at End of Treatment, as based on investigator judgement and clinical routine at the treating site, maximum 24 weeks post baseline per the IFU. After End of Treatment, subjects will continue in the investigation with wound management per clinical routine at the treating sites for 6 weeks. At 6 weeks post End of Treatment, subjects will attend a Follow-up visit to assess safety, wound status and relative change in wound size. Besides confirmation of the clinical performance and safety when used in a larger population the investigation also includes analysis of treatment period duration. Additionally, health economy parameters will be analyzed. The investigation will be monitored to confirm the already known precautions as well as identify new precautions and possible contraindications for the use of the device. Photography of the wound pre and post debridement will be performed to confirm wound size and amount of devitalized tissue in the wound.


Description:

As above


Recruitment information / eligibility

Status Terminated
Enrollment 34
Est. completion date November 20, 2023
Est. primary completion date November 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Chronic leg ulcers and chronic diabetic foot ulcers in need of debridement 2. Male or female, 18 years of age and above 3. Able to read and understand the Patient Informed Consent and to provide meaningful written informed consent Exclusion Criteria: 1. Known allergy/hypersensitivity to any of the components of ChloraSolv 2. Renal insufficiency defined as serum creatinine >200 µmol/L 3. Macroangiopathy expected to demand vascular intervention or percutaneous angioplasty performed less than 3 months after start of treatment; toe pressure <30mm Hg 4. Kidney or pancreas transplanted 5. Patient under cortisone treatment >60mg/day 6. Patient treated with chemotherapy or any other immune-inhibiting drugs 12 months before start of treatment 7. Other identified on-going pathologies in the area of wound, such as cancer 8. Pregnancy or breastfeeding 9. Subjects included in other ongoing clinical investigations which could interfere with this investigation, as judged by the investigator 10. Subjects not suitable for the investigation according to the investigator's judgment or other significant medical conditions that the investigator determines could interfere with compliance or investigation assessments.

Study Design


Intervention

Device:
ChloraSolv
Debridement with ChloraSolv until the wound is visually assessed as clean.

Locations

Country Name City State
Sweden Vårdcentralen Tunafors Eskilstuna
Sweden Carlanderska Hospital Göteborg
Sweden Wästerläkarna Göteborg
Sweden Capio Lundby Sjukhus Gothenburg
Sweden Wetterhälsan Munksjöstaden Jönköping
Sweden Orthopedic Clinic Mölndal Hospital Mölndal
Sweden Framtidens vårdavdelning Trelleborg

Sponsors (1)

Lead Sponsor Collaborator
RLS Global

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of clean wound bed at End of Treatment, as assessed by investigator When the investigator judges that the wound is clean primary endpoint is reached and confirmed by planimetry. 1 - 24 weeks
Secondary Relative change in devitalized tissue and wound size at End of Treatment, compared to Baseline, assessed by planimetry Assessed by planimetry 1 - 24 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03543007 - Evaluating the Safety and Efficacy of GrafixPL™PRIME for the Treatment of Chronic Venous Leg Ulcers N/A
Completed NCT05710094 - Safety and Tolerability of Single and Multiple Doses of SoftOx Biofilm Eradicator (SBE) in Chronic Leg Wounds Phase 1
Completed NCT03404297 - Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya N/A
Recruiting NCT05422248 - Oxygen Wound Therapy Feasibility Study N/A
Recruiting NCT03290690 - Positive Predictive Value (PPV) of Pseudomonas Aeruginosa
Enrolling by invitation NCT02619734 - Autologous Bone Marrow Stem Cells for Chronic Leg Ulcer Treatment in Sickle Cell Disease Phase 1
Completed NCT02696460 - Efficacy of 50% Nitrous Oxide/50% Oxygen Gas Premix in Chronic Leg Ulcer Debridement N/A